# Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older

> **NCT04537208** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 441 (actual)

## Conditions studied

- COVID-19 (Healthy Volunteers)

## Interventions

- **BIOLOGICAL:** CoV2 preS dTM-AF03 (low-dose)
- **BIOLOGICAL:** CoV2 preS dTM-AF03 (high-dose)
- **BIOLOGICAL:** CoV2 preS dTM-AS03 (low-dose)
- **BIOLOGICAL:** CoV2 preS dTM-AS03 (high-dose)
- **BIOLOGICAL:** CoV2 preS dTM (high-dose) without adjuvant
- **BIOLOGICAL:** Placebo (0.9% normal saline)

## Key facts

- **NCT ID:** NCT04537208
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-03
- **Primary completion:** 2021-11-19
- **Final completion:** 2021-11-19
- **Target enrollment:** 441 (ACTUAL)
- **Last updated:** 2025-09-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04537208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04537208, "Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04537208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*